Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Sensitivity of MRD Testing and Impact on Decisionmaking in ALL

February 1st 2020

Strategies to Assess Minimal Residual Disease

February 1st 2020

ALL: When and Who to Test for Minimal Residual Disease

February 1st 2020

MRD in ALL: Prognostic Importance and Multidisciplinary Care

February 1st 2020

Acute Lymphoblastic Leukemia: Optimal Timing of HSCT

February 1st 2020

ALL: Cytogenetics and T-Cell Versus B-Cell Induction Strategies

February 1st 2020

Induction Strategies for Philadelphia-Positive ALL

February 1st 2020

Considering Induction Regimens for ALL

February 1st 2020

Prognostic Factors in Acute Lymphoblastic Leukemia

February 1st 2020

Dr. Kreitman on the Use of Moxetumomab Pasudotox in Hairy Cell Leukemia

January 31st 2020

Robert J. Kreitman, MD, senior investigator and head of the Clinical Immunotherapy Section in the Laboratory of Molecular Biology at the National Cancer Institute, discusses the use of moxetumomab pasudotox-tdfk (Lumoxiti) in heavily pretreated patients with relapsed/refractory hairy cell leukemia (HCL).

Dr. Allan on the Use of Vecabrutinib Therapy in B-Cell Malignancies

January 31st 2020

John N. Allan, MD, assistant attending physician at NewYork-Presbyterian Hospital and assistant professor of medicine, Weill Cornell Medical College, Cornell University, discusses the use of vecabrutinib (SNS-062) therapy in patients with B-cell malignancies.

Dr. Bannerji on the Clinical Activity of the Bispecific Antibody REGN1979 in NHL

January 31st 2020

Rajat Bannerji, MD, PhD, hematologist/oncologist and chief of hematologic malignancies at the Rutgers Cancer Institute of New Jersey, discusses the clinical activity of the bispecific antibody REGN1979 in patients with non-Hodgkin lymphoma (NHL).

Future Directions and Unmet Needs for Treatment of DLBCL

January 30th 2020

Emerging Agents in the Management of R/R DLBCL

January 30th 2020

L-MIND Trial in Relapsed/Refractory DLBCL

January 30th 2020

Future Directions of CAR T Therapy in R/R DLBCL

January 30th 2020

R/R DLBCL: CAR T Therapy and Immune Checkpoint Inhibition

January 30th 2020

Safety and Efficacy of CAR T Therapy in R/R DLBCL

January 30th 2020

Use of CAR T Therapy in R/R DLBCL

January 30th 2020

Treatment Alternatives to Chemotherapy in R/R DLBCL

January 30th 2020